Toronto, Ontario -- April 26, 2012 --
Theralase Technologies Inc. (TSX-V: TLT) announced today that its innovative research
on Photo Dynamic Compound (PDC) destruction of bacteria, cancer cells and solid
subcutaneous (under the skin) animal tumours was recently presented at two major
international scientific conferences, demonstrating the significance and
validity of the research performed by Theralase’s world renowned and internationally
acclaimed scientists.
On January 23, 2012 in San Francisco, California at the BiOS SPIE
Photonics West Conference (the largest photonics conference in the world)
Theralase presented scientific research supporting a new cost effective
methodology to quickly quantify E. coli and Listeria bacteria. This new technology would be indispensable for
food manufacturing and handling facilities, restaurants, schools, nursing
homes, hospitals or any organization concerned with the early detection of
bacterial concentrations in food. Once these microorganisms have been quantified
with this new technology, they could be quickly destroyed utilizing Theralase’s
patented Photo Dynamic Compounds (PDCs) and proprietary light sources. A very
simple solution that could prove invaluable to an industry plagued with food
recalls that at recent estimates cost the industry over $157 billion a year in
North America alone and loss of life.
On April 19,
2012 in Brussels, Belgium at the Photonic Solutions for Better
Health Care (a division of Photonics Europe), Theralase presented new scientific
data supporting the application of Theralase’s anti-cancer PDCs to target and effectively
destroy a variety of cancer cells. The PDCs have also shown remarkable success
in the complete destruction of highly aggressive tumours in preclinical,
subcutaneous (under the skin) cancers in mice.
At the same conference, Theralase also
unveiled to the scientific community its advanced sterilization platform
technology that enables a 100% kill of life threatening infectious
microorganisms, such as staphylococcus aureus also known as "golden staph”.
Staphylococcus aureus (S. aureus) is
the most potent of the many staphylococcal species in existence and is a
leading cause of illness and death in humans despite the availability of numerous
antibiotics. Each year, more than 500,000 patients in
American hospitals contract a staphylococcal infection leading to 99,000 preventable deaths and adding an additional $35
to $45 billion in costs annually to the US healthcare system. (Source: Centers
for Disease Control and Prevention).
“Theralase is committed to the early commercialization of its patented
light activated Photo Dynamic Compounds (PDC) in the areas of anti-cancer and
anti-bacterial applications. This focus is
being used to develop a library of first-in-class light activated compounds
through various cancer and bacterial models, which are proving to be more
effective in low oxygen environments, preferentially preferred by cancer cells and
a number of different types
of bacteria. Theralase is on the path to substantial growth and the early
commercialization of our patented PDC technology in these fields, should facilitate exponential revenue increase.” said
Roger Dumoulin-White, President and CEO of Theralase. He added, “Our strong PDC
pipeline, one of the most innovative in the industry, has scientifically proven
that our PDC technology is capable of consistently producing 100% kill levels
across a wide range of bacteria and provides highly effective tumour destruction
in a mouse model. I am very proud of our scientific team
and pleased that their work was recognized and acknowledged by two of the
finest international academic assemblies worldwide; specifically: BiOS SPIE
Photonics West and Photonics Europe.”
About
Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops,
manufactures and markets patented, superpulsed laser technology utilized in
biostimulation and biodestruction applications. Theralase technology is safe
and effective in treating pain, inflammation and for tissue regeneration of
neural muscular skeletal conditions and wound healing. Theralase is currently
developing patented Photo Dynamic Compounds (PDCs) that are able to target and
destroy cancers, bacteria and viruses when light activated by Theralase’s
proprietary and patented laser technology.
For further information please visit www.theralase.com, regulatory
filings may be viewed by visiting www.sedar.com.
This press release contains
forward-looking statements which reflect the Company's current expectations
regarding future events. The forward-looking statements involve risks and
uncertainties. Actual results could differ materially from those projected
herein. The Company disclaims any obligation to update these forward-looking
statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the policies of the
TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of
this release.
